Neuman RI, van der Meer MMA, Nieboer D, et al. - Researchers here investigated the value of inhibin A and PAPP‐A2 (pregnancy‐associated plasma protein‐A2) for predicting preeclampsia‐related complications and determined how these compare with angiogenic biomarkers. They used a secondary analysis of a prospective, multicenter, observational study, aimed at evaluating the utility of sFlt‐1 (soluble Fms‐like tyrosine kinase‐1)/PlGF (placental growth factor) ratio, in order to determine inhibin A and PAPP‐A2 levels in 524 women with suspected/confirmed preeclampsia. Significantly increased levels of inhibin A and PAPP‐A2 were noted in women with preeclampsia and in maternal perfusate of preeclamptic placentas. The prediction of maternal complications improved significantly when inhibin A and PAPP‐A2 were added on top of the traditional criteria; gestational age, parity, proteinuria, and diastolic blood pressure. To differentiate fetal/neonatal complications on top of traditional criteria, inhibin A and PAPP‐A2 exhibited additive value but their discriminative value remained inferior to that of sFlt‐1/PlGF ratio or PlGF. The PAPP‐A2/PlGF ratio alone displayed remarkable predictive value for pregnancy complications, being superior to sFlt‐1/PlGF ratio in the case of maternal complications. Overall, findings suggest significant potential of inhibin A and PAPP‐A2 to predict preeclampsia‐related pregnancy complications and possibility of their beneficial effects on top of the angiogenic markers.